{"doi":"10.1021\/jm050438f","coreId":"136037","oai":"oai:bradscholars.brad.ac.uk:10454\/3191","identifiers":["oai:bradscholars.brad.ac.uk:10454\/3191","10.1021\/jm050438f"],"title":"Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells","authors":["Teesdale-Spittle, P.","Pors, Klaus","Brown, R.","Patterson, Laurence H.","Plumb, J.A."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2005","abstract":"NoA novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780\/ cp70 and A2780\/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780\/cp70 xenografted tumors in mice","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/3191<\/identifier><datestamp>\n                2016-10-25T11:29:38Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nDevelopment of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells<\/dc:title><dc:creator>\nTeesdale-Spittle, P.<\/dc:creator><dc:creator>\nPors, Klaus<\/dc:creator><dc:creator>\nBrown, R.<\/dc:creator><dc:creator>\nPatterson, Laurence H.<\/dc:creator><dc:creator>\nPlumb, J.A.<\/dc:creator><dc:subject>\nTreatment resistance<\/dc:subject><dc:subject>\nTransition metal Complexes<\/dc:subject><dc:subject>\nDivalent metal Complexes<\/dc:subject><dc:subject>\nPlatinum II Complexes<\/dc:subject><dc:subject>\nMalignant tumour<\/dc:subject><dc:subject>\nAlkylating agent<\/dc:subject><dc:subject>\nVertebrata<\/dc:subject><dc:subject>\nMammalia<\/dc:subject><dc:subject>\nRodentia<\/dc:subject><dc:subject>\nCell line<\/dc:subject><dc:subject>\nChlorine Organic compounds<\/dc:subject><dc:subject>\nAnimal<\/dc:subject><dc:subject>\nOvary<\/dc:subject><dc:subject>\nTumour cell<\/dc:subject><dc:subject>\nHuman<\/dc:subject><dc:subject>\nAlcohol<\/dc:subject><dc:subject>\nAntineoplastic agent<\/dc:subject><dc:subject>\nMechanism of action<\/dc:subject><dc:subject>\nAntimitotic<\/dc:subject><dc:subject>\nIntraperitoneal administration<\/dc:subject><dc:subject>\nChemotherapy<\/dc:subject><dc:subject>\nCytotoxicity<\/dc:subject><dc:subject>\nIn vivo<\/dc:subject><dc:subject>\nPyrrolidine derivatives<\/dc:subject><dc:subject>\nPiperidine derivatives<\/dc:subject><dc:subject>\nTricyclic compound<\/dc:subject><dc:subject>\nCondensed benzenic compound<\/dc:subject><dc:subject>\nStructure activity relation<\/dc:subject><dc:subject>\nDiphenols<\/dc:subject><dc:subject>\nAromatic amine<\/dc:subject><dc:subject>\nOvarian cancer<\/dc:subject><dc:subject>\nIn vitro<\/dc:subject><dc:subject>\nChemical synthesis<\/dc:subject><dc:subject>\nCisplatin<\/dc:subject><dc:description>\nNo<\/dc:description><dc:description>\nA novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780\/ cp70 and A2780\/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780\/cp70 xenografted tumors in mice.<\/dc:description><dc:date>\n2009-07-29T08:49:33Z<\/dc:date><dc:date>\n2009-07-29T08:49:33Z<\/dc:date><dc:date>\n2005<\/dc:date><dc:type>\nArticle<\/dc:type><dc:type>\nNo full-text available in the repository<\/dc:type><dc:identifier>\nPors, K., Plumb, J.A., Brown, R., Teesdale-Spittle, P., Searcey, M., Smith, P.J. and Patterson, L.H. (2005). Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells. Journal of Medicinal Chemistry. Vol. 48, No. 21, pp. 6690-6695.<\/dc:identifier><dc:identifier>\n90000186<\/dc:identifier><dc:identifier>\n90015088<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/3191<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1021\/jm050438f<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1021\/jm050438f"],"year":2005,"topics":["Treatment resistance","Transition metal Complexes","Divalent metal Complexes","Platinum II Complexes","Malignant tumour","Alkylating agent","Vertebrata","Mammalia","Rodentia","Cell line","Chlorine Organic compounds","Animal","Ovary","Tumour cell","Human","Alcohol","Antineoplastic agent","Mechanism of action","Antimitotic","Intraperitoneal administration","Chemotherapy","Cytotoxicity","In vivo","Pyrrolidine derivatives","Piperidine derivatives","Tricyclic compound","Condensed benzenic compound","Structure activity relation","Diphenols","Aromatic amine","Ovarian cancer","In vitro","Chemical synthesis","Cisplatin"],"subject":["Article","No full-text available in the repository"],"fullText":null}